FDA final guidance sets a risk-based potency assurance roadmap for cell and gene therapies, spanning development, manufacturing controls, lot release assays, and monitoring.
|Articles|December 17, 2014
- Breast Cancer (Issue 1)
- Volume 1
- Issue 1
Immune Checkpoint Inhibition in Breast Cancer
Author(s)Edith A. Perez, MD
Edith A. Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, comments on immune checkpoint inhibition for the treatment of breast cancer.
Advertisement
Edith A. Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, comments on immune checkpoint inhibition for the treatment of breast cancer.
Articles in this issue
almost 12 years ago
Breast Ultrasound Added to Mammography Increases Cancer Detectionalmost 12 years ago
Biomarker-Driven Trial of Novel Topo-1 Inhibitor Debutedalmost 12 years ago
Anti-Androgen Not for Male Cancers Alonealmost 12 years ago
Trials Seek Optimal nab-Paclitaxel Regimen for First-Line Use in TNMBCalmost 12 years ago
Obesity as a Risk Factor for Inflammatory Breast Canceralmost 12 years ago
Advances in the Treatment of HER2-Positive Breast CancerAdvertisement
Related to this article
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Amivantamab and Hyaluronidase for Recurrent/Metastatic HNSCC
2
Zocilurtatug Pelitecan Shows Activity in epNEC Across DLL3 Expression Levels
3
LITESPARK-011 Raises Questions About RCC Treatment Sequencing
4
Dr Mohamed on Zocilurtatug Pelitecan for Refractory Extrapulmonary NEC
5